Ionis Pharmaceuticals (IONS) announced that Tryngolza has been approved in the European Union as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome. The approval follows the opinion of the Committee for Medicinal Products for Human Use.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Arrowhead files complaint for declaratory judgment against Ionis
- Ionis Pharmaceuticals: Buy Rating Backed by Breakthrough Therapy Designation and Promising Clinical Results for ION582
- Ionis Pharmaceuticals granted breakthrough therapy designation to ION582
- Ionis Pharmaceuticals price target raised to $80 from $70 at RBC Capital
- Ionis Pharmaceuticals’ Olezarsen Shows Strong Potential in Billion-Dollar Market, Earning Buy Rating from Analyst